FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • May 5th, 2005 • Maxim Pharmaceuticals Inc • Medicinal chemicals & botanical products • New York
This First Amendment (the “Amendment”) to the License Agreement dated March 1, 2004 (the “Agreement”) by and between: (a) on the one hand, Shire BioChem Inc. (“SBI”), a corporation organized and existing under the laws of Canada and wholly-owned subsidiary of Shire, having its principal office at 275 Armand-Frappier Boulevard, Laval, Quebec, Canada H7V 4A7; and (b) on the other hand, Maxim Pharmaceuticals, Inc. (“Maxim”), a corporation incorporated and existing under the laws of the State of Delaware, having its principal office at 8899 University Center Lane, Suite 400, San Diego, California 92122, U.S.A, and Cytovia, Inc. (“Cytovia”), a corporation incorporated and existing under the laws of the State of Delaware and a wholly-owned subsidiary of Maxim, having the same principal office as Maxim (Maxim and Cytovia are hereinafter collectively referred to as “MPI”), is entered into as of January 26th, 2005 (the “Amendment Date”). Capitalized terms used but not otherwise defined herein s
